SAM

Sectoral Asset Management Portfolio holdings

AUM $125M
1-Year Est. Return 68.15%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+68.15%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$162M
AUM Growth
+$10.6M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
98
New
Increased
Reduced
Closed

Top Buys

1
+$6.01M
2
+$3.4M
3
+$3.06M
4
ANAB icon
AnaptysBio
ANAB
+$2.54M
5
TECX
Tectonic Therapeutic
TECX
+$1.94M

Top Sells

1
+$28.6M
2
+$7.54M
3
+$2.43M
4
REPL icon
Replimune Group
REPL
+$2.15M
5
PVLA
Palvella Therapeutics
PVLA
+$2.07M

Sector Composition

1 Healthcare 97.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
76
Jazz Pharmaceuticals
JAZZ
$11.3B
$296K 0.18%
2,244
-30
ILMN icon
77
Illumina
ILMN
$19.7B
$259K 0.16%
2,727
-55
INCY icon
78
Incyte
INCY
$19.4B
$257K 0.16%
3,030
-3,030
PCVX icon
79
Vaxcyte
PCVX
$8.29B
$151K 0.09%
4,205
MRNA icon
80
Moderna
MRNA
$21.3B
$145K 0.09%
5,600
AXSM icon
81
Axsome Therapeutics
AXSM
$8.18B
$124K 0.08%
1,020
MLTX icon
82
MoonLake Immunotherapeutics
MLTX
$1.28B
$6.86K ﹤0.01%
956
-14,152
CNC icon
83
Centene
CNC
$21.3B
– –
-12,500
CRSP icon
84
CRISPR Therapeutics
CRSP
$5.53B
– –
-2,540
CVRX icon
85
CVRx
CVRX
$218M
– –
-73,500
IOBT icon
86
IO Biotech
IOBT
$23.7M
– –
-117,691
LEGN icon
87
Legend Biotech
LEGN
$3.26B
– –
-19,627
MEDP icon
88
Medpace
MEDP
$13.3B
– –
-531
REPL icon
89
Replimune Group
REPL
$585M
– –
-231,650
RVMD icon
90
Revolution Medicines
RVMD
$19.3B
– –
-6,240
RXRX icon
91
Recursion Pharmaceuticals
RXRX
$1.85B
– –
-11,500
SRRK icon
92
Scholar Rock
SRRK
$4.63B
– –
-10,380
TRML
93
DELISTED
Tourmaline Bio
TRML
– –
-116,510
VTRS icon
94
Viatris
VTRS
$16.7B
– –
-19,800
LENZ
95
LENZ Therapeutics
LENZ
$378M
– –
-977,245
KMTS
96
Kestra Medical Technologies
KMTS
$1.34B
– –
-35,000
CAI
97
Caris Life Sciences
CAI
$5.43B
– –
-8,350
GMED icon
98
Globus Medical
GMED
$12B
– –
-13,500
1 2 3
4